The key mechanisms of action of the laser were first discovered by Albert Einstein in the early 1900s. Initial results from the use of a carbon dioxide laser for the management of cervical dysplasia were initially less successful than anticipated because of the inability to determine appropriate depth of penetration for prevention of recurrent disease. Not until 1978 did Anderson and Hartley emphasize the actual mechanics for the depth of cervical involvement. [1] Laser technique was further refined and shown to be both practical and efficacious by Jordan in 1985 [2] and by Dorsey in 1979, [3] when the Greater Baltimore Medical Center published the first clinical experience with cervical conizations by carbon dioxide laser. See the image below.
Lasers have provided the laparoscopic surgeon with an efficient method of achieving rapid excision, coagulation, or vaporization of pelvic abnormalities. Most familiar is therapy for pelvic endometriosis or adhesions. When laser is used in combination with other laparoscopic instruments, the variety of procedures performed with the laparoscope may be enhanced. Laser Co2 Skin Resurfacing
The carbon dioxide laser has been considered an effective modality for multiple tasks related to the treatment of intraepithelial neoplasia of the lower genital tract, most commonly for large lesions and for multifocal manifestations of human papilloma virus (HPV). The use of this technology is limited in some areas because of healthcare provider training and experience and because of a lack of availability of equipment. Many hospitals require that specific credentials be obtained before using this modality, including documentation of didactic instruction and clinical supervision of initial procedures.
Since the earliest use of the CO2 laser for managing squamous abnormalities of the lower genital tract and intra-abdominal treatment of endometriosis and adhesions, it has been employed for other medical therapies including : treatment of condylomata in women who are pregnant, [4] treatment of Bartholin gland cysts and abscesses, [5] ablation of pigmented follicular cysts of the vulva, [6] treatment of chronic anal fissures, [7] excision of an imperforate hymen, [8] excision of a vaginal septum, [8] excision of hypertrophied labia minora [9] or vaginal polyps, [8] management of Nabothian cysts [8] and even to assist the treatment and care of girls who have had type III female genital mutilation. [10]
The CO2 laser has also been utilized as an option for management of anal dysplasia [11] or treatment of refractory ano-genital lichen sclerosis. [12, 13]
Intra-abdominal use of the CO2 laser is now being compared to other instruments such as the ultrasonic scalpel and employed via robotic management of endometriosis. It is of value in not only resection of endometriotic implants and treatment of endometriomas, but of value in deep endometriotic implants and in combination with bowel resections for endometriosis. [14, 15] Case reports also address the use of the CO2 laser in the laparoscopic resection of myomas and adenomyomas. [16, 17] A flexible, fully articulated CO2 laser delivery system has been utilized in robotic myomectomy. [18] Other traditional uses of the CO2 laser laparoscopically included ovarian “drilling” or even wedge resection for adjuvant therapy of women with polycystic ovaries to assist ovulation. [19]
The most recent focus of attention on gynecologic use of the carbon dioxide laser has been as a treatment option for vulvovaginal rejuvenation and vaginal atrophy. Most studies fail to cite the absence of FDA approval of this device for this purpose and report observational case studies or case series with success defined as patient reports of satisfaction. Little mention is made of postoperative adhesions or pain or need for retreatments (duration of therapy). Although the FDA did clear a fractional CO2 laser for indications of “incision, ablation, vaporization and coagulation of body soft tissues in medical specialties including genitourinary surgery”, the indication for treatment of genital atrophy was not listed. The American College of Obstetricians and Gynecologists (ACOG) published a position statement about fractional laser treatment of vulvovaginal atrophy in 2016 and reaffirmed this position statement July 2018. [20] ACOG has also published a Committee Opinion on vaginal “rejuvenation” and cosmetic vaginal procedures. [21]
Observational studies utilizing the CO2 laser for vaginal atrophy generally lack comparison to other treatment modalities and have no long-term follow-up. [22, 23] A randomized, double-blind, placebo-controlled clinical trial compared the CO2 laser with topical estriol alone, and with use of laser and topical estriol together. It enrolled 45 women and assessed symptoms, vaginal appearance, and vaginal maturation at 8 and 20 weeks and noted increased pain in the laser alone group at 8 weeks, but at 20 weeks female sexual function scores were comparable for all groups (estriol alone, estriol and CO2 laser, and CO2 laser alone). [24] Another study assessed epidermal thickness in an effort to more quantify results of CO2 laser use in women with vaginal atrophy.
A multicenter, randomized trial by Paraiso et al compared fractionated CO2 laser with estrogen cream in menopausal women who significant vaginal atrophy symptoms. After 6 months, similar improvement in symptoms, in addition to urinary and sexual function, was noted with both treatments. [25]
A randomized trial by Li et al compared fractional CO2 laser treatment with sham treatment in 85 women who had postmenopausal vaginal symptoms. After 12 months, the researchers found no significant difference in symptom severity or quality of life between women who received laser treatment and those who had a sham treatment. [26]
Intraepithelial neoplasia is a descriptive histologic term for squamous abnormalities of the vulva (VIN) and perianal area, vagina (VAIN) and cervix (CIN) (see the images below).
In 2012, the College of American Pathology (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP) developed and published the Lower Anogenital Squamous Terminology (LAST) project. This presented the current terminology used to describe Human Papilloma virus associated squamous lesions of the anogenital tract. [27] In the LAST system, histologic cervical findings are described using the same terminology as cytologic findings.
LSIL: low grade squamous intraepithelial lesions - now replaces the designation of CIN I, or mild dysplasia. This category also includes abnormalities previously designated as CIN 2 (moderated dysplasia) which are negative for p16 immunostaining.
HSIL:high grade squamous intraepithelial lesions-represent abnormalities previously designated CIN 3 (severe dysplasia) and also includes prior CIN 2 lesions which are p16 positive, as well as encompassing those cellular abnormalities designated carcinoma in situ. [27]
The ASCCP published in 2012 updated consensus guidelines for the management of abnormal cervical screening tests, but continues to use the terminology CIN (cervical intraepithelial neoplasia), as delegates to the LAST project determined that the classification of LSIL and HSIL does not yet have enough evidence to allow clear risk-based management guidelines. [28]
Pelvic pain related to adhesions or endometrial implants also represents a significant disease burden in the United States. Adhesions may be filmy or dense and may involve any pelvic structures. Endometrial implants may be clear or cystic, red or brown/black. Customarily, the older lesions are more darkly colored and accompanied by an increased depth of involvement with contracture of surrounding peritoneum or tissue surfaces. As the severity of endometriosis increases, the presence and severity of adhesions may also increase and become denser. Visual evaluation of endometriosis may not completely correlate with depth of invasion of implants or with the patient's clinical symptoms.
The precision of the carbon dioxide laser delivered laparoscopically lends itself to intra-abdominal and intrapelvic adhesiolysis or ablation of endometrial implants.
According to the US Centers for Disease Control and Prevention, HPV is so common that almost everyone will be infected at some time in their lives. [29]
In 2005, the US Centers for Disease Control and Prevention estimated that 20 million Americans are DNA positive for anogenital types of human papillomavirus at any time. [30] Almost one half of sexually active adolescents or young adults aged 15-24 years may be infected by the human papillomavirus. In the United States, 6.2 million individuals are estimated to become newly infected with human papillomavirus annually.
The most likely etiology of lower genital tract squamous abnormalities is infection with HPV, a double-stranded DNA virus of the Papovaviridae family. The HPV has more than 100 subtypes and is the major causative factor of malignant and premalignant squamous abnormalities of the anogenital tract. Serotypes associated with squamous lesions may be designated as having a high or low risk for progression to malignancy. Ultimate cure of the viral infection can only be achieved by the immune system of the human host.
Papillomaviruses are ubiquitous in higher vertebrates. Approximately 40 types of HPV infect the genital tract. Intercellular cytokine-mediated control plays an important role in suppression of malignant transformation. A genetic change in pathways controlling intracellular or intercellular signaling may allow progression to a malignant phenotype. [31]
Treatment modalities, such as the carbon dioxide laser, destroy or excise infected cells, thus reducing the amount of infected tissue and, presumably, the host viral load. The subsequent healing process of the host stimulates viral combat at the surgical site. Patients with abnormal cytology findings or visible lesions must first be evaluated with visual inspection using a colposcope to help determine the location, extent, and severity of the clinical abnormalities. Colposcopically directed biopsies are indicated when dysplasia is present or malignancy is considered, in the clinical opinion of the healthcare provider. Findings from one or more biopsy samples from the involved areas help document the location and histologic severity of the disease.
The carbon dioxide laser has been used for ablating high-grade lesions or excising abnormal areas, including the transformation zone of the cervix. Ablation may frequently be used for treating VIN and is also considered to be a treatment modality for VAIN requiring therapy.
In the pelvis, endometriosis has been hypothesized to be a result of endometrial cells producing disease in areas outside of the uterus, most likely by retrograde menstrual flow via patent fallopian tubes, but also potentially via vascular or lymphatic channels. Altered immune function within the peritoneal cavity, plus other potential factors, then permit development of endometrial implants, most frequently on the ovaries or in the cul-de-sac. Other sites in the abdomen or pelvis or remote sites may become involved.
Within the pelvis, the CO2 laser can be used to ablate affected sites or excise the peritoneum, thus improving anatomic relationships by lysing adhesions and excising endometrial implants.
When used in the pelvis for therapy of adhesions of other etiologies (eg, postoperative or postinfectious), the CO2 laser allows precise incision of the adhesions, restoring local anatomy with a primary goal of reduced, repeat adhesion formation and decreased risk of damage to adjacent structures.
The carbon dioxide laser is customarily chosen over other ablative or excisional techniques when great precision is needed, particularly in situations involving large surface areas or when precise control over the depth of penetration is desired. Examples of procedures for which the carbon dioxide laser is indicated include (1) ablation or excision of dysplasia in situations in which minimization of tissue destruction or removal is desired; (2) cervical treatment combined with treatment of dysplasia or condylomata of the vulva, vaginal, perineal, or perirectal areas; (3) multifocal disease of the cervix, vagina, or vulva/perianal areas; (4) ablation or excision of endometrial implants or affected peritoneum; and (5) lysis of intra-abdominal or intrapelvic adhesions.
The carbon dioxide laser is used in conjunction with a laparoscope or colposcope. This allows precise application, which is one advantage of this treatment modality. Another advantage of the laser is hemostasis and minimal thermal necrosis (< 100 µm) when properly set. In addition, the procedure time is brief, and the laser may be used in an office or outpatient setting with the patient under local anesthesia when treating the vulva, vagina, or cervix. The office setting may also be more economical than procedures performed in a surgical suite. Surgical advantages of the intra-abdominal CO2 laser include (1) rapid incision and vaporization, (2) safety and predictability, and (3) lack of contact with the organ.
Patients with abnormal cervical cytology findings must first be evaluated using a colposcope to help determine the location, extent, and severity of the clinical abnormalities. Colposcopically directed biopsies are indicated when the health care provider has determined dysplasia is present. Findings from 1 or more biopsy samples from the involved areas and findings from an endocervical curettage help document the location and histologic severity of the disease present.
The carbon dioxide laser has been used for ablating CIN or excising abnormal areas, including the cervical transformation zone.
Patients with visible lesions of the vagina, grossly compatible with HPV-related disorders, may be inspected with the colposcope and biopsy performed if the provider suspects dysplasia or to exclude malignancy.
Visible lesions of the vulva or perineum and perianal areas may indicate a need for biopsy to evaluate dysplasia, exclude malignancy, or further elucidate dermatologic disorders. The colposcope with or without acetic acid to the vulva may be invaluable in determining the presence or extent of disease while providing focused light in the area of interest.
The CO2 laser may be used whenever a diagnostic laparoscopic procedure can combine a diagnosis of disease and the extent of disease with immediate therapy. It may also be used to augment pain management associated with endometriotic implants via partial excision of the peritoneum or through laser destruction of the medial aspect of the uterosacral ligaments, interrupting nerve endings associated with central pelvic pain.
Contraindications to using the carbon dioxide laser for the treatment of lower genital tract disease include (1) an inability to visualize the area to be treated because of anatomic considerations (eg, prolapsing lateral vaginal sidewall), (2) preoperative histology findings indicative of malignancy, and (3) inadequate physician training or experience. Laser ablation is contraindicated if the entire lesion is not visible, although excisional procedures may be performed.
Contraindications to laparoscopic use of the CO2 laser include (1) inability to visualize the site to be treated without risk of damage to adjacent structures, (2) anatomic findings not consistent with the diagnosis of endometriosis or adhesions (eg, neoplasm), (3) inadequate physician training or experience.
Anderson MC, Hartley RB. Cervical crypt involvement by intraepithelial neoplasia. Obstet Gynecol. 1980 May. 55(5):546-50. [QxMD MEDLINE Link].
Jordan JA, Woodman CB, Mylotte MJ, et al. The treatment of cervical intraepithelial neoplasia by laser vaporization. Br J Obstet Gynaecol. 1985 Apr. 92(4):394-8. [QxMD MEDLINE Link].
Dorsey JH, Diggs ES. Microsurgical conization of the cervix by carbon dioxide laser. Obstet Gynecol. 1979 Nov. 54(5):565-70. [QxMD MEDLINE Link].
Arena S, Marconi M, Frega A, Villani C. Pregnancy and condyloma. Evaluation about therapeutic effectiveness of laser CO2 on 115 pregnant women. Minerva Ginecol. 2001 Dec. 53 (6):389-96. [QxMD MEDLINE Link].
Figueiredo AC, Duarte PE, Gomes TP, Borrego JM, Marques CA. Bartholin's gland cysts: management with carbon-dioxide laser vaporization. Rev Bras Ginecol Obstet. 2012 Dec. 34 (12):550-4. [QxMD MEDLINE Link].
Chuang YH, Hong HS, Kuo TT. Multiple pigmented follicular cysts of the vulva successfully treated with CO2 laser: case report and literature review. Dermatol Surg. 2004 Sep. 30 (9):1261-4. [QxMD MEDLINE Link].
Esfahani MN, Madani G, Madhkhan S. A novel method of anal fissure laser surgery: a pilot study. Lasers Med Sci. 2015 Aug. 30 (6):1711-7. [QxMD MEDLINE Link].
González-Isaza P, Lotti T, França K, Sanchez-Borrego R, Tórtola JE, Lotti J, et al. Carbon Dioxide with a New Pulse Profile and Shape: A Perfect Tool to Perform Labiaplasty for Functional and Cosmetic Purpose. Open Access Maced J Med Sci. 2018 Jan 25. 6 (1):25-27. [QxMD MEDLINE Link].
Frega A, Verrone A, Schimberni M, Manzara F, Ralli E, Catalano A, et al. Feasibility of office CO2 laser surgery in patients affected by benign pathologies and congenital malformations of female lower genital tract. Eur Rev Med Pharmacol Sci. 2015. 19 (14):2528-36. [QxMD MEDLINE Link].
Penna C, Fallani MG, Fambrini M, Zipoli E, Marchionni M. Type III female genital mutilation: clinical implications and treatment by carbon dioxide laser surgery. Am J Obstet Gynecol. 2002 Dec. 187 (6):1550-4. [QxMD MEDLINE Link].
Weis SE. Current treatment options for management of anal intraepithelial neoplasia. Onco Targets Ther. 2013. 6:651-65. [QxMD MEDLINE Link].
Lee A, Lim A, Fischer G. Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosus. Australas J Dermatol. 2016 Feb. 57 (1):39-43. [QxMD MEDLINE Link].
Peterson CM, Lane JE, Ratz JL. Successful carbon dioxide laser therapy for refractory anogenital lichen sclerosus. Dermatol Surg. 2004 Aug. 30 (8):1148-51. [QxMD MEDLINE Link].
Meuleman C, Tomassetti C, D'Hoore A, Buyens A, Van Cleynenbreugel B, Fieuws S, et al. Clinical outcome after CO₂ laser laparoscopic radical excision of endometriosis with colorectal wall invasion combined with laparoscopic segmental bowel resection and reanastomosis. Hum Reprod. 2011 Sep. 26 (9):2336-43. [QxMD MEDLINE Link].
Meuleman C, Tomassetti C, Wolthuis A, Van Cleynenbreugel B, Laenen A, Penninckx F, et al. Clinical outcome after radical excision of moderate-severe endometriosis with or without bowel resection and reanastomosis: a prospective cohort study. Ann Surg. 2014 Mar. 259 (3):522-31. [QxMD MEDLINE Link].
Choussein S, Srouji SS, Farland LV, Gargiulo AR. Flexible Carbon Dioxide Laser Fiber Versus Ultrasonic Scalpel in Robot-Assisted Laparoscopic Myomectomy. J Minim Invasive Gynecol. 2015 Nov-Dec. 22 (7):1183-90. [QxMD MEDLINE Link].
Barton SE, Gargiulo AR. Robot-assisted laparoscopic myomectomy and adenomyomectomy with a flexible CO2 laser device. J Robot Surg. 2013 Jun. 7 (2):157-62. [QxMD MEDLINE Link].
ESGE Special Interest Group ‘Innovations’ Working Group. Lasers in gynaecology - Are they still obsolete? Review of past, present and future applications. Facts Views Vis Obgyn. 2020 May 7. 12 (1):63-6. [QxMD MEDLINE Link]. [Full Text].
Ostrzenski A. Endoscopic carbon dioxide laser ovarian wedge resection in resistant polycystic ovarian disease. Int J Fertil. 1992 Sep-Oct. 37 (5):295-9. [QxMD MEDLINE Link].
Fractional Laser Treatment of Vulvovaginal Atrophy and U.S. Food and Drug Administration Clearance: Position Statement. ACOG. Available at https://www.acog.org/Clinical-Guidance-and-Publications/Position-Statements/Fractional-Laser-Treatment-of-Vulvovaginal-Atrophy-and-US-Food-and-Drug-Administration-Clearance. May 2016; Accessed: September 20, 2018.
Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 378: Vaginal "rejuvenation" and cosmetic vaginal procedures. Obstet Gynecol. 2007 Sep. 110 (3):737-8. [QxMD MEDLINE Link].
Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017 May. 28 (5):681-685. [QxMD MEDLINE Link].
Mortensen OE, Christensen SE, Løkkegaard E. The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state-of-the-art review. Acta Obstet Gynecol Scand. 2022 Jun. 101 (6):657-92. [QxMD MEDLINE Link]. [Full Text].
Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FLA, Santiago LHS, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018 Jan. 25 (1):21-28. [QxMD MEDLINE Link].
Paraiso MFR, Ferrando CA, Sokol ER, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause. 2020 Jan. 27 (1):50-6. [QxMD MEDLINE Link].
Li FG, Maheux-Lacroix S, Deans R, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA. 2021 Oct 12. 326 (14):1381-9. [QxMD MEDLINE Link]. [Full Text].
Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013 Jan. 32(1):76-115. [QxMD MEDLINE Link].
Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 2012 ASCCP Consensus Guidelines Conference. J Low Genit Tract Dis. 2013 Apr. 17(5 Suppl 1):S1-S27. [QxMD MEDLINE Link].
CDC. Human papillomavirus (HPV): know the facts. Centers for Disease Contol and Prevention. September 30, 2015. Available at http://www.cdc.gov/hpv/hcp/know-facts.html. Accessed: November 5, 2015.
Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007 Jun 1. 195(11):1582-9. [QxMD MEDLINE Link]. [Full Text].
zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000 May 3. 92(9):690-8. [QxMD MEDLINE Link].
McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ). 1999 Jan. 1-6. [QxMD MEDLINE Link].
Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. Proyecto Epidemiologico Guanacaste Group. J Natl Cancer Inst. 2008 Apr 2. 100(7):513-7. [QxMD MEDLINE Link].
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep. 189(1):12-9. [QxMD MEDLINE Link].
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov. 11(11):1048-56. [QxMD MEDLINE Link].
Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6. 348(6):518-27. [QxMD MEDLINE Link].
Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003 Jan 1. 95(1):46-52. [QxMD MEDLINE Link].
Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008 Oct 13. 337:a1754. [QxMD MEDLINE Link].
Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011 Jul. 20(7):1398-409. [QxMD MEDLINE Link].
Gajjar K, Martin-Hirsch PP, Bryant A. Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment. Cochrane Database Syst Rev. 2012 Oct 17. 10:CD006120. [QxMD MEDLINE Link].
Vanichtantikul A, Charoenkwan K. Lidocaine spray compared with submucosal injection for reducing pain during loop electrosurgical excision procedure: a randomized controlled trial. Obstet Gynecol. 2013 Sep. 122(3):553-7. [QxMD MEDLINE Link].
Kofoed K, Norrbom C, Forslund O, Møller C, Frøding LP, Pedersen AE, et al. Low prevalence of oral and nasal human papillomavirus in employees performing CO2-laser evaporation of genital warts or loop electrode excision procedure of cervical dysplasia. Acta Derm Venereol. 2015 Feb. 95 (2):173-6. [QxMD MEDLINE Link].
Wisniewski PM, Warhol MJ, Rando RF, Sedlacek TV, Kemp JE, Fisher JC. Studies on the transmission of viral disease via the CO2 laser plume and ejecta. J Reprod Med. 1990 Dec. 35(12):1117-23. [QxMD MEDLINE Link].
Bellina JH, Stjernholm RL, Kurpel JE. Analysis of plume emissions after papovavirus irradiation with the carbon dioxide laser. J Reprod Med. 1982 May. 27(5):268-70. [QxMD MEDLINE Link].
OSHA. Laser/Electrosurgery Plume. United States Department of Labor, Occupational Safety & Health Administration. Available at http://www.osha.gov/SLTC/laserelectrosurgeryplume/index.html. Accessed: March 10, 2009.
Salvatore S, Leone Roberti Maggiore U, Athanasiou S, Origoni M, Candiani M, Calligaro A, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015 Aug. 22 (8):845-9. [QxMD MEDLINE Link].
Dorsey JH. Laser surgery for cervical intraepithelial neoplasia. Chohan N, Barron HA, eds. Obstetrics and Gynecology Clinics of North America. Philadelphia, Pa: WB Saunders Company; 1991. 475-489.
Reid R. Physical and surgical principles of laser surgery in the lower genital tract. Chohan N, Barron HA, eds. Obstetrics and Gynecology Clinics of North America. Philadelphia, Pa: WB Saunders and Company; 1991. 429-74.
Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 1998 Nov. 92(5):737-44. [QxMD MEDLINE Link].
Gardeil F, Barry-Walsh C, Prendiville W, Clinch J, Turner MJ. Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III. Obstet Gynecol. 1997 Mar. 89(3):419-22. [QxMD MEDLINE Link].
Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol. 2002 Sep. 86(3):365-9. [QxMD MEDLINE Link].
Mathevet P, Dargent D, Roy M, Beau G. A randomized prospective study comparing three techniques of conization: cold knife, laser, and LEEP. Gynecol Oncol. 1994 Aug. 54(2):175-9. [QxMD MEDLINE Link].
Spitzer M. Vaginal estrogen administration to prevent cervical os obliteration following cervical conization in women with amenorrhea. J Low Genit Tract Dis. 1997 Apr. 1(2):53-6. [QxMD MEDLINE Link].
Sadler L, Saftlas A. Cervical surgery and preterm birth. J Perinat Med. 2007. 35(1):5-9. [QxMD MEDLINE Link].
Sjoborg KD, Vistad I, Myhr SS, et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand. 2007. 86(4):423-8. [QxMD MEDLINE Link].
Jancar N, Rakar S, Poljak M, Fujs K, Kocjan BJ, Vrtacnik-Bokal E. Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. Eur J Gynaecol Oncol. 2006. 27(3):239-42. [QxMD MEDLINE Link].
Kjellberg L, Wadell G, Bergman F, et al. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol. 2000 Nov. 183(5):1238-42. [QxMD MEDLINE Link].
Solomon D, Schiffman M, Tarone R, et al. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001 Feb 21. 93(4):293-9. [QxMD MEDLINE Link].
Bar-Am A, Daniel Y, Ron IG, et al. Combined colposcopy, loop conization, and laser vaporization reduces recurrent abnormal cytology and residual disease in cervial dysplasia. Gynecol Oncol. 2000. 78:47-51. [QxMD MEDLINE Link].
dos Santos L, Odunsi K, Lele S. Clinicopathologic outcomes of laser conization for high-grade cervical dysplasia. Eur J Gynaecol Oncol. 2004. 25(3):305-7. [QxMD MEDLINE Link].
Klobucar A, Hrgovic Z, Bukovic D, et al. The treatment of cervical dysplasia with laser. Med Arh. 2004. 58(6):355-7. [QxMD MEDLINE Link].
Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr. 1996. (21):17-25. [QxMD MEDLINE Link].
Ueda M, Ueki K, Kanemura M, et al. Diagnostic and therapeutic laser conization for cervical intraepithelial neoplasia. Gynecol Oncol. 2006 Apr. 101(1):143-6. [QxMD MEDLINE Link].
Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005 Mar 1. 191(5):731-8. [QxMD MEDLINE Link].
Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May-Jun. 62(3):147-72. [QxMD MEDLINE Link]. [Full Text].
Pink surface after removing char
White, fibrous arcuate vessels seen
*Adapted from Obstetrics and Gynecology Clinics of North America, Lasers in Gynecology [48]
Janice L Bacon, MD Practicing Physician and Partner, Women’s Health and Diagnostic Center, Lexington Medical Center; Consultant Physician in Contraception, Department of Health and Environmental Control Janice L Bacon, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Society for Colposcopy and Cervical Pathology, Association of Reproductive Health Professionals, North American Society for Pediatric and Adolescent Gynecology, South Carolina Medical Association Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Received salary from Medscape for employment. for: Medscape.
Christine Isaacs, MD Associate Professor, Department of Obstetrics and Gynecology, Division Head, General Obstetrics and Gynecology, Medical Director of Midwifery Services, Virginia Commonwealth University School of Medicine Christine Isaacs, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists Disclosure: Nothing to disclose.
Laser Co2 Skin Resurfacing Karen Loeb Lifford, MD Director of General Gynecology, Associate Program Director, Department of Obstetrics and Gynecology, Instructor, Brigham and Women's Hospital, Harvard Medical School Karen Loeb Lifford, MD is a member of the following medical societies: Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, Phi Beta Kappa Disclosure: Nothing to disclose.